Vaxcyte (PCVX) CEO reports 100,000-share transfer to an irrevocable trust

Rhea-AI Filing Summary

Vaxcyte, Inc. director and CEO Grant Pickering reported an internal share transfer involving company common stock. On January 14, 2026, an entity associated with him transferred 100,000 shares of common stock to an irrevocable trust for estate planning purposes, with a reported price of $0 per share, indicating this was not an open‑market sale. The footnote explains that he no longer has a pecuniary interest in those shares and therefore disclaims beneficial ownership.

Following the transaction, 400,908 common shares are reported as directly owned. In addition, 136,215 common shares are held by a trust for the benefit of his son and another 136,215 common shares are held by a trust for the benefit of his daughter, both reported as indirectly owned through children’s trusts.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PICKERING GRANT

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/14/2026		G		100,000(1)	D	$0	400,908	D
Common Stock								136,215	I	By Children's Trust(2)
Common Stock								136,215	I	By Children's Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involves the Reporting Person's transfer of shares to an irrevocable trust for estate planning purposes. The Reporting Person no longer has a pecuniary interest in the shares and therefore disclaims beneficial ownership.

2. Shares are held directly by a trust for the benefit of the Reporting Person's son.

3. Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

Remarks:

	Grant Pickering, by /s/ Peter N. Efremenko, Attorney-In-Fact	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Vaxcyte (PCVX) report for Grant Pickering?

The filing reports the transfer of 100,000 shares of Vaxcyte common stock on January 14, 2026 to an irrevocable trust, coded as a G transaction (a transfer).

Was the 100,000-share Vaxcyte transfer by the CEO a market sale?

The transaction shows a price of $0 per share and is described as a transfer to an irrevocable trust for estate planning, indicating it was not an open‑market sale.

Does Grant Pickering still have an economic interest in the 100,000 Vaxcyte shares?

The footnote states that, after the transfer to the irrevocable trust, the reporting person no longer has a pecuniary interest in those shares and disclaims beneficial ownership.

How many Vaxcyte shares does Grant Pickering report owning after the transaction?

After the reported transfer, 400,908 common shares are listed as directly owned. Additionally, 136,215 shares are held by a trust for his son and 136,215 shares by a trust for his daughter, reported as indirect ownership.

What is the relationship of Grant Pickering to Vaxcyte, Inc.?

Grant Pickering is reported as both a director and an officer of Vaxcyte, serving as the company’s Chief Executive Officer.

What do the children’s trusts in the Vaxcyte Form 4 represent?

Separate footnotes explain that 136,215 shares are held by a trust for the benefit of the reporting person’s son and another 136,215 shares by a trust for the benefit of his daughter, both reported as indirectly owned.